Immatics N.V. (IMTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Immatics N.V. (IMTX) closed at USD 7.00 on 2026-10-14, a change of -32.4 % over the past year, with a market capitalization of USD 1.09B.

Immatics N.V. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Immatics N.V. key figures

Previous close

USD 7.00 (2026-10-14)

1-year change

-32.4 %

Market cap

USD 1.09B

Enterprise value

USD 597.22M

P/E ratio (trailing)

-3.82

P/E ratio (forward)

-3.53

EPS (trailing)

-1.87

EPS (forward)

-2.03

PEG ratio

n/a

Price to book

2.19

Revenue growth

93 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.07

Employees

704

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Immatics N.V.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Immatics N.V. and compare it with other stocks.